Even in the UK, routine testing for MAML2 rearrangement in mucoepidermoid carcinoma has been the norm only since 2015–2016 with FISH the most widely available test, whereas MYB testing in adenoid cystic carcinoma is still only available in a handful of specialist centres. The gene discussed is MAML2; the disease is mucoepidermoid carcinoma.